For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Mildronate is a registered trademark of the Grindex. Its active substance is meldonium. Meldonium is a limited-market pharmaceutical, and is an anti-ischemic' drug, which means it is used to treat inadequate blood-flow to the organs, especially the heart. It is primarily used to treat patients with heart conditions that affect the body's ability to deliver oxygen to the body. It helps to protect against tissue damage from angina attacks, chronic heart failure and disorders of brain circulation.
Mildronate dihydrate production has high technology barrier and is technology intensive industry. Currently, there are several producing companies in the Europe mildronate dihydrate industry. The main market player is Grindeks.
Mildronate dihydrate mainly has three existence forms, which include mildronate dihydrate capsule, mildronate dihydrate injection and mildronate dihydrate tablet. With medical effect of mildronate dihydrate, the downstream application industries will need more mildronate dihydrate products. So far, it isn't approved by the FDA in the United States.
The major raw materials for mildronate dihydrate are tert-Butyl acrylate (TBA), unsymmetrical dimethylhydrazine (UDMH) and ethanol, etc. Fluctuations in the price of the upstream product will impact on the production cost of mildronate dihydrate, and then impact the price of mildronate dihydrate. The production cost of mildronate dihydrate is also an important factor which could impact the price of mildronate dihydrate. The mildronate dihydrate manufacturers are trying to reduce production cost by developing production method.
Over the next five years, LPI(LP Information) projects that Mildronate Dihydrate will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.
This report studies the global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa, focuses on the top 5 players in each region, with sales, price, revenue and market share from 2013 to 2018, the top players:
Market Segment by Regions, this report splits Global into several key Regions, with sales, revenue, market share of top players in these regions, from 2013 to 2018 (forecast), like
- North America (United States, Canada and Mexico)
- Asia-Pacific (China, Japan, Southeast Asia, India and Korea)
- Europe (Germany, UK, France, Italy and Russia etc.)
- South America (Brazil, Chile, Peru and Argentina)
- Middle East and Africa (Egypt, South Africa, Saudi Arabia)
Split by Product Types, with sales, revenue, price, market share of each type, can be divided into
Split by applications, this report focuses on sales, market share and growth rate in each application, can be divided into
- Cardiovascular Disease